Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Sweetens Early-Stage Diabetes Pipeline With HGS’ Albugon

This article was originally published in The Pink Sheet Daily

Executive Summary

The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.

You may also be interested in...



Human Genome Sciences CEO Is Former TAP President Thomas Watkins

Watkins joins HGS after serving as head of TAP Pharmaceuticals for six years. HGS focused its CEO search on candidates with late-stage product development experience; the firm's lead candidate LymphoStat-B is in Phase II for RA and lupus.

Human Genome Sciences CEO Is Former TAP President Thomas Watkins

Watkins joins HGS after serving as head of TAP Pharmaceuticals for six years. HGS focused its CEO search on candidates with late-stage product development experience; the firm's lead candidate LymphoStat-B is in Phase II for RA and lupus.

Liraglutide Phase III Diabetes Program Delayed Until 2005

Novo Nordisk expects its glucagon-like peptide-1 analog liraglutide to enter Phase III trials in 2005

Related Content

Topics

UsernamePublicRestriction

Register

PS057937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel